https://techcrunch.com/2020/06/12/cue-healths-portable-fast-covid-19-test-gains-fda-emergency-approval/ > Fresh off a $100 million Series C funding round, molecular diagnostics startup Cue Health has more good news – it has received an Emergency Use Authorization (EUA) for its rapid, point-of-care COVID-19 test. The company got a $13 million grant from BARDA in March to help it scale its development and deployment of rapid diagnostics, and its COVID-19 test is obviously a key focus of that effort given the current global pandemic. > Cue’s test is portable, and uses an RNA detection method to confirm the presence of the actual virus in a patient’s system using nasal swab samples. The company says that it can provide results in as little as 25 minutes, and it’s relatively simple to administer, both factors that make it potentially very useful in efforts to scale COVID-19 testing as the pandemic and its ensuing global health crisis continues.